Lennon Paul, Deady Sandra, Healy Maire L, Toner Mary, Kinsella John, Timon Conrad I, O'Neill James P
Department of Otolaryngology, Head and Neck Surgery, St. James's Hospital, Dublin, Ireland.
National Cancer Registry - Ireland, Cork, Ireland.
Head Neck. 2016 Apr;38 Suppl 1:E1122-9. doi: 10.1002/hed.24170. Epub 2016 Feb 16.
Anaplastic thyroid cancer has a median survival between 1.2 and 10 months. The purpose of our study was to evaluate the outcomes of patients with anaplastic thyroid cancer in Ireland.
We carried out a retrospective analysis of the Irish National Cancer Database for patients with anaplastic thyroid cancer between 2000 and 2010.
Of a total of 64 patients (40 women, 24 men), the median age was 69 years, and 29.7% of the patients had distant metastases. The overall median survival was 2.3 months and the 1, 2, and 5-year survival was 12.5%, 6.25%, and 4.69%, respectively. On univariate analysis age, sex, metastases at diagnosis, and multimodality treatment were statistically significant indicators of prognosis, and metastases at diagnosis remained statistically significant on multivariate analysis.
These results correlate with the American Thyroid Association (ATA) guidelines, in which, when possible, multimodality therapy offers a survival advantage to a select group of patients. Novel therapies may offer the greatest hope for these patients. © 2016 Wiley Periodicals, Inc. Head Neck 38: E1122-E1129, 2016.
间变性甲状腺癌的中位生存期在1.2至10个月之间。我们研究的目的是评估爱尔兰间变性甲状腺癌患者的治疗结果。
我们对爱尔兰国家癌症数据库中2000年至2010年间的间变性甲状腺癌患者进行了回顾性分析。
在总共64例患者（40名女性，24名男性）中，中位年龄为69岁，29.7%的患者有远处转移。总体中位生存期为2.3个月，1年、2年和5年生存率分别为12.5%、6.25%和4.69%。单因素分析显示，年龄、性别、诊断时的转移情况和多模式治疗是预后的统计学显著指标，多因素分析显示诊断时的转移情况仍具有统计学显著性。
这些结果与美国甲状腺协会（ATA）指南相关，其中，在可能的情况下，多模式治疗为部分患者提供了生存优势。新的治疗方法可能为这些患者带来最大的希望。©2016威利期刊公司。头颈外科38：E1122-E1129，2016。
